Active Biotech AB publ
F:BTPC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Active Biotech AB publ
F:BTPC
|
SE |
|
J
|
Johnson Controls International PLC
F:TYIA
|
IE |
|
P
|
Phillips Edison & Co Inc
F:9R4
|
US |
|
S
|
Semirara Mining and Power Corporation
XPHS:SCC
|
PH |
|
K
|
Kansas City Southern
LSE:0JQ4
|
US |
|
A
|
Akwel SA
SWB:MW4
|
FR |
|
Progyny Inc
NASDAQ:PGNY
|
US |
|
Sumitomo Electric Industries Ltd
OTC:SMTOF
|
JP |
|
W
|
Wix.Com Ltd
F:W1X
|
IL |
|
Hyatt Hotels Corp
NYSE:H
|
US |
|
T
|
Teck Resources Ltd
SWB:TEKB
|
CA |
|
W
|
White Mountains Insurance Group Ltd
F:WNI
|
US |
|
C
|
China Telecom Corp Ltd
XMUN:ZCH
|
CN |
|
E
|
Estee Lauder Companies Inc
LSE:0JTM
|
US |
|
Rheinmetall AG
XETRA:RHM
|
DE |
|
Knight-Swift Transportation Holdings Inc
NYSE:KNX
|
US |
|
H
|
Huron Consulting Group Inc
F:HUR
|
US |
Active Biotech AB publ
Active Biotech is a Swedish biotech company that develops drug candidates for diseases such as cancer, inflammatory disorders, and autoimmune conditions. It does not run a big drug-manufacturing business; instead, it focuses on discovering molecules, testing them in clinical trials, and advancing the most promising programs toward approval. Its work is aimed at finding treatments that can be licensed to larger drug companies or taken forward with partners. The company makes money mainly through collaboration deals, licensing agreements, and potential milestone or royalty payments tied to successful drug development and future sales. Its main counterparts are pharmaceutical partners, research institutions, and eventually healthcare systems and patients if a drug reaches the market. Because biotech development is expensive and risky, this business model depends heavily on finding the right scientific targets and building partnerships that can share the cost and reward. What makes Active Biotech different is that it sits early in the drug value chain, before most of the commercial work begins. That means its value comes from scientific assets and development expertise rather than from selling products itself. For investors, it is best understood as a research-driven drug developer whose outcomes depend on the progress of a small number of pipeline programs.
Active Biotech is a Swedish biotech company that develops drug candidates for diseases such as cancer, inflammatory disorders, and autoimmune conditions. It does not run a big drug-manufacturing business; instead, it focuses on discovering molecules, testing them in clinical trials, and advancing the most promising programs toward approval. Its work is aimed at finding treatments that can be licensed to larger drug companies or taken forward with partners.
The company makes money mainly through collaboration deals, licensing agreements, and potential milestone or royalty payments tied to successful drug development and future sales. Its main counterparts are pharmaceutical partners, research institutions, and eventually healthcare systems and patients if a drug reaches the market. Because biotech development is expensive and risky, this business model depends heavily on finding the right scientific targets and building partnerships that can share the cost and reward.
What makes Active Biotech different is that it sits early in the drug value chain, before most of the commercial work begins. That means its value comes from scientific assets and development expertise rather than from selling products itself. For investors, it is best understood as a research-driven drug developer whose outcomes depend on the progress of a small number of pipeline programs.
